

Court Of Appeal Makes Decision Following Ruling That Nice Process On Anti-Dementia Medicines Unfair, UK

Eisai and Pfizer announced on May 9th that the Court of Appeal had released its decision on the consequential issues arising from Court of Appeal's recent ruling that the process by which the National Institute for Health and Clinical Excellence (NICE) decided to restrict anti-dementia medicines for newly diagnosed patients with mild Alzheimer's disease was procedurally unfair. **The Court has decided that NICE must make available to all consultees a copy of the fully executable version (FEV) of the cost-effectiveness model used to produce guidance for the treatment of patients with Alzheimer's**

- Eisai and other consultees have a period of 42 days from receipt of the FEV in which to review the model and make representations to NICE
- NICE has been refused permission to appeal to the House of Lords
- NICE is on public record as stating that, "in the meantime, and in accordance with the judges' ruling, we will provide Eisai with an executable version of the economic model used in our appraisal, so that they may comment on it. We will then take those comments into account."
- If NICE's calculations to determine the cost-efficacy of anti-dementia medicines contain errors or are unreliable, the NICE Appraisal Committee will be required to review their recommendations in light of any such fresh evidence submitted.